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Abstract
Background: Tumor-predominant splice isoforms were identified during comparative in silico
sequence analysis of EST clones, suggesting that global aberrant alternative pre-mRNA splicing may
be an epigenetic phenomenon in cancer. We used an exon expression array to perform an
objective, genome-wide survey of glioma-specific splicing in 24 GBM and 12 nontumor brain
samples. Validation studies were performed using RT-PCR on glioma cell lines, patient tumor and
nontumor brain samples.
Results: In total, we confirmed 14 genes with glioma-specific splicing; seven were novel events
identified by the exon expression array (A2BP1, BCAS1, CACNA1G, CLTA, KCNC2, SNCB, and
TPD52L2). Our data indicate that large changes (> 5-fold) in alternative splicing are infrequent in
gliomagenesis (< 3% of interrogated RefSeq entries). The lack of splicing changes may derive from
the small number of splicing factors observed to be aberrantly expressed.
Conclusion: While we observed some tumor-specific alternative splicing, the number of genes
showing exclusive tumor-specific isoforms was on the order of tens, rather than the hundreds
suggested previously by in silico mining. Given the important role of alternative splicing in neural
differentiation, there may be selective pressure to maintain a majority of splicing events in order to
retain glial-like characteristics of the tumor cells.
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Background
In alternative pre-mRNA splicing, multiple transcript iso-
forms are expressed from a single gene by varying the
combination of exons that are included in the mature
mRNA. These isoforms may differ in their transcript and
protein stabilities and/or in their protein structures and
activities, which allows for functional and physiological
diversity [1,2]. Alternative splicing affects up to 74% of all
genes and may cause epigenetic instability when aberrant
[3]. In cancer, two major mechanisms lead to the dysreg-
ulation of proper splicing: somatic mutations in splice
regulatory cis-elements and mis-expression of trans-acting
factors [4,5]. The second phenomenon has been reported
in numerous cancers including glioma, ovarian and colon
cancer [6-11]. Furthermore, many individual genes have
cancer-predominant splicing patterns that contribute to
tumorigenesis [5,12,13]. However, it is unclear whether
the tumor-specific misexpression of splice factors leads to
global aberrant splicing in cancer. Genome-wide attempts
to address this have been performed mostly in silico by
aligning and comparing EST libraries. Several hundred
isoforms appear to be unique to tumor libraries, but these
analyses are largely incomplete as they can miss known
isoforms and are intrinsically biased in their scoring of
single clones [14-20].
Of all tissues, the brain has the most cassette exon alterna-
tive splicing [21,22]. This tissue-specific splicing is respon-
sible for proper neural cell differentiation and
neurotransmitter signaling that may be misregulated to
allow stem-cell like proliferation to form brain tumors
[23-27]. Gliomas are glial-like tumors, with glioblastoma
(GBM) being the most severe form [28]. Independent and
in silico genome-wide assessments have identified genes
expressing particular splice isoforms more frequently in
glioma than in normal brain. Among the 27 individual
(Table 1; see Additional file 1) and the five in silico studies
(see Additional file 2), only three of the genes, BIN1, MAX
and MPZL1 were in common. Because of these discrepan-
cies, we performed a global, unbiased study using the
human exon expression array (Affymetrix) to experimen-
tally identify common glioma-specific aberrant splicing
events and misexpressed splicing factors. Our data indi-
cate that overall aberrant tumor-specific cassette exon
splicing events involve small changes, less than 5-fold.
Few splicing factors had dramatically altered expression in
glioma, but could be targeting the genes that were identi-
fied as having significant glioma-specific splicing in our
study.
Results
Exon array analysis
To measure significant alternative splicing changes associ-
ated with primary brain tumors, we compared genome-
wide exon expression levels of 24 grade IV glioblastoma
(GBM) and 12 nontumor brain samples using the Human
Exon Array 1.0 ST (Affymetrix, Santa Clara, CA) [29]. Mul-
tiple statistical algorithms were developed to identify
alternative pre-mRNA splicing events (see Methods). The
Differential Expression (DE) value describes the difference
in the average expression of all exons for a given RefSeq
entry between two groups of samples (tumor vs. nontu-
mor). A DE = 0 indicates no change in transcript expres-
sion between the two groups, a DE < 0 and a DE > 0
indicates decreased or increased gene expression in the
disease group, respectively. The Alternative Splicing (AS)
score was generated to identify all types of alternative pre-
mRNA splicing events as detected by differential hybridi-
zation of a PSR (probe selection region). The higher the
AS score for a given RefSeq entry, the greater the extent to
which at least one PSR deviated in its differential hybridi-
zation compared with all other probe sets in that RefSeq.
To assign a biologically relevant parameter to the AS score,
we performed modeling of a cassette exon splicing event
for a 3-exon gene. This gave median theoretical AS scores
when comparing a 5% level of exon inclusion in one sam-
ple with a 25%, 50%, and 100% inclusion level in the sec-
ond sample of 38.3, 78.7 and 132.9, respectively. As a
final parameter, we included a p-value calculation, which
indicates the probability that an AS score would show the
presence of alternative splicing. We focused on a core set
of RefSeq entries (20,157) with p-values of less than 0.05,
and used the DE value plotted against the AS score to eval-
uate the relationship between expression and change in
alternative splicing.
Examination of FGFR1 glioma-specific splicing by exon 
array
In order to assess the specificity, sensitivity and feasibility
of an array-based, genome-wide approach to identify
Table 1: Previous individual reports of GBM-associated alternative splicing
Gene Ontology Process Genes
Cell Growth/Apoptosis CDKN2B, FGFR1, MDM2, MIA, NF1, RSU-1, TP73
Cell Mobility/Cell Adhesion CALD1, CD44, CRK, FN1, MAP2, ADAM22, PECAM1, TNC
Transport CACNA1G, CYP27B1, SLC1A2, KCNMA1
Transcription MAX, RFX4, TCF4
Other FLJ12438, NRP1, SEMA6B/HAS, SR2c
See Additional file 1 for referencesBMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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alternative splice events, we determined the effect of alter-
ing a glioma-specific splicing event in U251 cells. Anti-
sense morpholino oligonucleotides were used to switch
exon 3 inclusion in FGFR1  mRNA precursors from its
aberrant skipping to inclusion, as occurs in normal brain
[30] (Figure 1A Inset). Figure 1A shows the plot of DE vs.
AS values for 20,157 core set RefSeq entries from this exon
array experiment. The FGFR1-specific splicing switch was
easily distinguishable for five FGFR1 RefSeq entries that
include probesets that monitor exon 3 inclusion (Figure
1A; see Additional file 3). The change in exon 3 splicing
led to significant AS scores (81.99 to 91.68, p-value < 0.05;
see Additional file 4), which were well above the median
derived value for a 10-fold increase in exon inclusion.
Finally, the DE values between 0.38 to 0.89 also agreed
with RT-PCR results that showed little change in FGFR1
expression when splicing of exon 3 was altered.
The induced FGFR1 splicing switch also caused a large
change in the splicing score of NRG1 (AS score of 82.57,
p-value < 0.05). However, the hybridization map and RT-
PCR validation suggest it is a cross-hybridization artifact
(see Additional file 3). There were 16 other RefSeq entries,
representing 11 genes that showed significant (p-values <
0.05) changes in exon 1 usage after treatment (see Addi-
tional file 4). These changes may be regulated by the effect
of exon 3 inclusion on FGFR1 signaling. Overall, the
U251 experiments confirmed that targeted changes in
alternative splicing of cassette exons would be reflected in
high AS scores and p-values < 0.05 on the exon array.
These data indicated the general feasibility of the exon
array and our analytical approach to identify cassette exon
changes on a genome-wide level.
Detection of alternative splicing in GBM patient samples
Next, we compared the genome-wide exon expression lev-
els in 24 GBM and 12 nontumor samples (Figure 1B; see
Additional file 5 for RefSeq entries with significant p-val-
ues < 0.05). The shape and distribution of the RefSeq val-
ues differed greatly for the patient samples compared to
the FGFR1 experiment. Only four genes had AS scores
above the derived median for a 10-fold change in splicing
(CNTNAP4, HIST1H3B, MAL2 and MOBP; see Additional
file 3). Unlike FGFR1, these genes had high levels of dif-
ferential expression between nontumor and tumor sam-
ples, which appeared to impact their AS scores. CNTNAP4
and HIST1H3B are intronless genes that do not represent
alternative splicing. The event in MAL2 involved exon 1
and could not be explained by alternative splicing. The
event identified for MOBP was not amenable to RT-PCR
verification (see Additional file 3). Finally, a significant 3'
splice site event was predicted in the heat map of NKX6-2,
which could not be confirmed by RT-PCR (Figure 1A; see
Additional file 3, and data not shown).
In the absence of readily identifiable large splicing
changes, we went on to validate our algorithm parame-
ters. From several hundred manually examined RefSeq
entries, we chose to validate over 50 genes with hybridiza-
tion heatmaps suggestive of cassette exon pre-mRNA
splicing. These genes represented a broad range of AS
scores, DE values, and p-values (Figure 2A). Validation
was performed by semi-quantitative RT-PCR on three gli-
oma cell lines (U251, SNB19 and T98G), a normal brain
control, and a subset of samples from the patient set used
for the array experiments (Figure 2B). We could make con-
fident conclusions for 38 (76%) of these genes (see Addi-
tional file 6). We chose to exclude the remaining genes
from our analysis due to low expression levels, which
made it difficult to make definitive interpretations. The 38
genes were represented by a total of 78 RefSeq entries,
with 43 entries exhibiting p-values < 0.05. Five entries had
AS scores that were greater than the derived median for a
5-fold change in splicing. We confirmed glioma-specific
splicing for eight genes represented by 21 RefSeq entries:
A2BP1, BCAS1, CACNA1G, CALD1, CLTA, KCNC2, SNCB
and TPD52L2. The most dramatic cassette exon changes
occurred in regions where the DE values approached 0
and the AS scores were above 13 as was the case with both
CLTA and TPD52L2. The lack of glioma-specific splicing
was confirmed for 12 genes (26 RefSeq entries) with p-
value > 0.05: ALG12,  CASP2,EMID1,  FGFR1,  PCNT2,
LAIR1,  MDM2,  MNT,  NAV2,  PACSIN1,  PECAM1  and
TPM1. Overall, RT-PCR results were concordant with array
data for 47 of 78 RefSeq entries (60%). The majority of
nonconcordant samples were for genes that had p-values
< 0.05, where glioma-specific splicing could not be con-
firmed (false-positives; 11 genes represented by 22 RefSeq
entries, or 28%). The statistical filtering missed at least six
glioma-specific splicing events (false-negatives). These
genes had varying degrees of glioma-specific splicing and
included APPA4, CLTB, DYNC1I2, NF1, RTN4 and TNC
(Figure 2; see Additional file 6). However, RT-PCR data
suggested that most of these genes would have had AS
scores exceeding the 5-fold threshold with the exception
of NF1 and CLTB. Figure 2B shows the RT-PCR results of
10 representative genes. In total, we found 14 genes with
glioma-specific splicing: A2BP1,  APPA4,  BCAS1,
CACNA1G, CALD1, CLTA, CLTB, DYNC1I2, KCNC2, NF1,
RTN4, SNCB, TNC and TPD52L2.
As an additional step to determine the accuracy of the
exon array platform and our algorithm, we specifically
queried previously reported GBM-specific splicing events
within our dataset. Figure 3A plots the array values
obtained in our patient set for 32 independently identi-
fied GBM-specific pre-mRNA splicing events (Table 1),
represented by a total of 55 RefSeq entries (see Additional
files 1 and 8). For all of these genes, the AS scores fell
below the derived 5-fold change in splicing (the highestBMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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Comparative genome-wide exon expression analyses in glioma cell lines and patient samples Figure 1
Comparative genome-wide exon expression analyses in glioma cell lines and patient samples. Differential Expres-
sion (DE) values are plotted against Alternative Splicing (AS) scores for a defined set of 20,157 RefSeq entries. (A) Plot showing 
the average of three independent experiments for U251 glioblastoma cells in which FGFR1 exon 3 splicing was changed using 
targeted antisense morpholino oligonucleotide-treatment. The positions of five RefSeq entries representing FGFR1 are indi-
cated. The inset shows representative RT-PCR results for FGFR1 exon 3 splicing following treatment with the control (MO-C) 
or antisense (MO-T) oligonucleotide. For data on RefSeq entries with significant values see Additional file 4. (B) Plot showing 
the genome-wide changes in expression and splicing observed in GBM compared to nontumor brain. For each Ref Seq entry, 
the values are derived from 24 GBM samples minus 12 nontumor brain samples. Notable RefSeq entries are labeled with their 
gene names. For data on RefSeq entries with significant values see Additional file 5. The theoretical values for a 5-fold (dashed 
line) and 10-fold (dotted line) change in exon inclusion are shown. For hybridization intensity maps of the highlighted genes see 
Additional file 3.BMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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Evaluation of glioma-specific splicing events Figure 2
Evaluation of glioma-specific splicing events. (A) Plot of values extracted from Figure 1B examined by RT-PCR. False-
negative samples had p-values > 0.05, but showed glioma-specific splicing by RT-PCR. False-positive samples had p-values < 
0.05, but had no glioma-specific splicing by RT-PCR. Notable RefSeq entries are labeled with their gene names. The theoretical 
value for a 5-fold change in exon inclusion is shown (dashed line). For data on RefSeq entries with significant values see Addi-
tional file 6. (B) Representative RT-PCR validation results. The left panel shows RT-PCR results for nontumor brain (NB) and 
three GBM cell lines (GBM CL): U251 (1), SNB19 (2), and T98G (3). The right panel shows RT-PCR results for four nontumor 
brain samples and eight GBM tumor samples. The arrows indicate the isoform(s) that is differentially expressed in GBM; the 
involved exons are schematically presented to the right (NB, nontumor brain; GBM, GBM tumor brain). MBP and UBE2C were 
not observed to generate GBM-specific bands. GAPDH was used as a loading control. MW, molecular weight marker. For 
hybridization intensity maps for the highlighted genes see Additional file 7.BMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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An array-based examination of published and in silico-predicted glioma-specific events Figure 3
An array-based examination of published and in silico-predicted glioma-specific events. (A) Plot of values extracted 
from Figure 1B showing RefSeq entries that monitor published glioma-specific splicing events (Table 1). The circled RefSeq 
entries include confirmed negative splicing events. For data on RefSeq entries with significant values see Additional file 1. (B) 
Plot showing positions of 267 RefSeq entries from Figure 1B that were identified by five in silico studies [15–18, 20]. The open 
squares show 11 RefSeq events that were concordant in more than one study (discussed in the text). Notable RefSeq entries 
are labeled with their gene names. The theoretical value for a 5-fold change in exon inclusion is shown (dashed line). For data 
on RefSeq entries with significant values see Additional file 2. For the hybridization intensity maps for the highlighted genes see 
Additional file 8.BMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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was 18.12 in CAMK2A). Only CALD1, CACNA1G and
CAMK2A had p-values < 0.05 that predicted strong differ-
ential splicing, while BIN1, CD44, RFX4 and TNC had AS
scores close to that of CAMK2A, showing small changes in
splicing. Validation of a subset of these genes (CACNA1G,
CALD1,FGFR1, MDM2, NF1, PECAM1 and TNC) by semi-
quantitative RT-PCR confirmed GBM-specific splicing for
four of seven (~60%) reported splicing events: CACNA1G,
CALD1, NF1 and TNC (Figures 2B and 3A; see Additional
file 8). CACNA1G had enhanced exon inclusion in the gli-
oma cell lines, with a less pronounced change in the GBM
patient samples (data not shown). The CALD1 differential
exon inclusion event was present predominantly in gli-
oma cell lines and GBM patient samples. For TNC, the
GBM patient samples had more exon inclusion compared
with the nontumor brain samples, which was opposite to
the cell lines and previously reported findings [31]. In
NF1, both cell line and patient samples had greatly
enhanced inclusion of exon 23A, which agreed with pub-
lished findings [14]. The results for FGFR1 were inconclu-
sive since the glioma cell lines showed the expected
predominant skipping of exon 3 compared with our nor-
mal brain control, but enhanced exon skipping was not as
prominent in the patient samples. The three remaining
genes (MBD1, MDM2 and PECAM1) had no detectable
GBM-specific splicing, consistent with their low AS scores
(circled in Figure 3A). Therefore, the RT-PCR analyses on
these seven published events were consistent with array-
derived results except for exon 23A of NF1, which was not
represented by an established RefSeq.
Low concordance with in silico studies
Previous in silico studies identified at least 186 genes with
purported glioma-specific splicing events [15-18,20]. Fig-
ure 3B plots the array values obtained in our patient set for
these genes (represented by 265 RefSeq entries; see Addi-
tional file 2). Only 13 of 265 RefSeq entries had p-values
< 0.05 (see Additional file 8). Most of the genes had only
small changes in differential expression (the majority
clustered at DE = 0). Low AS scores suggest that the
reported splicing events are infrequent, which could
explain the lack of concordance among the studies. CLTA
and TPD52L2 had clear, verifiable glioma-specific splicing
patterns by both exon array and RT-PCR (Figure 2A, 2B
and 3B; see Additional files 7 and 8); they were also listed
in one of these reports [18]. MBP and UBE2C had p-values
< 0.05 (Figure 2A and 3B). However, RT-PCR analysis
failed to validate the presence of a consistent glioma-spe-
cific splicing event (Figure 2B).
Expression profiling of RNA processing factors
Recently, upregulation of the splicing factor SF2/ASF was
shown to be oncogenic [11]. To determine changes in
splicing factor expression, we also performed expression
profiling on a subset of 10 GBM and 10 nontumor sam-
ples using the established U133 Plus 2 expression array.
Overall, only 13 of 499 probe sets queried (2.6%) showed
significant differences (> 4-fold, p-value < 0.05) in expres-
sion levels between GBM and nontumor samples (see
Additional file 9). To determine whether splice factor
expression could be used as a marker of gliomagenesis, we
performed an unsupervised clustering analysis. In this
clustering, the samples separated into GBM and nontu-
mor groups with the exception of a single nontumor sam-
ple (data not shown). Clustering of the 25 most
differentially expressed probe sets with significant p-val-
ues representing 19 unique genes (see Additional file 10)
is shown in Figure 4. The majority of these genes are not
known to be associated with alternative splicing. How-
ever, three splice factors could be linked to GBM-specific
splicing events having p < 0.05 (see Additional file 9):
A2BP1 regulates CLTB, GRIN1, MAG, NF1 and SCN8A
splicing, PTB regulates CLTB, GABA,  GRIN  and  FGFR2
splicing, and CUGBP2 regulates RASGRF1 splicing [32-
35].
Discussion
Aberrant pre-mRNA splicing may be an important epige-
netic factor for tumor progression. However, it is unclear
how many genes are mis-spliced in a given tumor and
whether aberrant expression of splice factors is responsi-
ble for their appearance. We used an exon array and
designed analytical algorithms and parameters to identify
GBM-specific splicing events in an unbiased manner. By
plotting scores for differential expression (DE) against
those for alternative splicing (AS) for genes and exons
interrogated by the exon array, we were able to distinguish
a single targeted induced splicing change in FGFR1 among
20,157 RefSeq entries and to monitor the concomitant
splicing and gene expression changes. Using the same
approach for comparing an extended GBM and nontumor
sample set, GBM-specific splicing events of similar magni-
tude were not identified, which suggests that large-scale
aberrant splicing in GBM are infrequent. We do not dis-
count the fact that individual instances of dramatic
changes in splicing were present; however, they were not
shared by the majority of samples. The lack of events with
large changes in differential exon expression led us to
mine our data for splicing changes with at least a 2-fold
change in probe set hybridization (AS score) and a p-value
< 0.05. In the hundreds of heatmaps examined, there were
many changes indicative of the usage of alternative pro-
moters or polyadenylation sites. However, we chose to
focus on cassette exons as events that could be readily
examined by RT-PCR. This led to the validation of 14
GBM-specific events: A2BP1, APPA4, BCAS1, CACNA1G,
CALD1,  CLTA,CLTB,  DYNC1I2,  KCNC2,  NF1,  RTN4,
SNCB, TNC and TPD52L2. Moreover, our expression pro-
filing analysis indicated that there were relatively few
GBM-specific changes for splicing regulators. Among theBMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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genes with the greatest differential expression only A2BP1,
CUGBP2, ELAV1, MBNL2, PTBP1 and YBX1, have known
functions in alternative splicing. At least three of these
(A2BP1, PTBP1 and CUGBP2) could be linked to GBM-
specific splicing events.
The identified and validated GBM-specific isoforms
encode proteins that primarily affect cell growth and
mobility. A2BP1, which shows both differential expres-
sion and splicing, is a neuronal-specific splicing regulator
for multiple targets [36]. CLTB and DYNC1I2 are involved
Differential expression of RNA processing factors in GBM tumors Figure 4
Differential expression of RNA processing factors in GBM tumors. Expression analysis was performed on 10 GBM 
tumor and 10 nontumor samples using the Affymetrix U133A Plus 2 platform. Two-way hierarchical clustering analysis of the 
25 most differential probe sets with p-value < 0.05 is shown. For detailed information on the probe sets and their functions For 
the hybridization intensity maps for the highlighted genes see Additional file 10.BMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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in intracellular transport and may play a role in cell migra-
tion [37,38]. Four genes have clearly identified functions
in the central nervous system: APPA4 functions in Notch
signaling during neural development, cell adhesion and
apoptosis; RTN4 is a neurite growth inhibitor; and SNCB,
which is upregulated in glial tumors, is thought to regu-
late phospholipase D2 activity. NF1 is believed to be a
glial-cell marker and mutated in multiple CNS tumors
[14,39]. For the remaining genes, little is known about
their function in normal brain or gliomagenesis. Compar-
ing glioblastoma and oligodendroglioma as two histolog-
ical glioma subgroups on the same exon array platform
that we used here, French and colleagues recently identi-
fied a total of 11 differentially expressed splice variants
[40], one of which overlapped with our validated genes
(CAMK2A) (see Additional file 1). In the exon array study
for prostate and colon cancer, only CALD1 was in com-
mon with our validated gene list [29,33]. Therefore, it is
unclear whether common pathways are targeted for splic-
ing changes during tumorigenesis. It remains to be deter-
mined whether these splicing targets have a synergistic
effect on gliomagenesis.
Genes with glioma-predominant splice isoforms have pre-
viously been identified through global EST alignments.
MAX was the only gene found both experimentally and in
silico (see Additional files 1 and 2). Despite using similar
datasets, the number of in silico derived genes with GBM-
specific isoforms varied and only three genes were found
to be shared between two of the five studies: AP2A1,
CPNE1 and KPNB1 [14,15,17,26,27]. The lack of agree-
ment between all of these studies can be explained by sev-
eral technical and biological factors. First, the small
sample sizes used did not allow for statistical calculations.
Second, sample heterogeneity affected normalization and
interpretation. Third, the nature of the samples being
compared, which can be normal or nontumor vs. tumor,
or tumor type A vs. tumor type B. For EST libraries, the true
splicing frequency could be masked by too few ESTs, nor-
malization strategies, and/or low-stringency criteria that
enriched for rare ESTs [41,42]. The bias towards 3' and 5'
ends of transcripts could also lead to the under-represen-
tation of isoforms with internal differences [41,42]. In
contrast, using a large sample set on exon arrays circum-
vented these problems and allowed for objective measure-
ments of isoform frequencies. It should be noted,
however, that array-based studies are limited by the qual-
ity of the target preparation, probe specificity and sensitiv-
ity, and for the Affymetrix platform we used the lack of
interrogation of exons < 25 bp., and can be confounded
by tumor tissue heterogeneity. Of our 14 validated GBM-
associated splicing events, eight (CAMK2A,CACNA1G,
CALD1, CLTA, NF1,RTN4, TNC and TPD52L2) were pre-
viously reported (see Additional files 1 and 2). Most of the
genes that were discordant had splicing changes that were
outside the range of detection for the array (less than 2-
fold). Two additional genes (MBP and UBE2C) had a p-
value < 0.05 that were concordant with in silico deter-
mined genes, but could not be validated by RT-PCR (Fig-
ure 2B). Finally, the lack of complete agreement in all of
these gene lists could be due to the overall low level of
aberrant splicing in GBM.
Many studies have shown that overexpression of a single
cancer-enhancing isoform is sufficient to alter glioma cell
proliferation or invasion [43-45]. What remains unclear is
how these specific isoforms are produced. Many cancers
have over- or under-expression of splicing factors, which
suggests that global aberrant splice events are possible.
However, our analysis revealed that aberrant splicing fac-
tor expression does not lead to either large changes in spe-
cific exon utilization or widespread changes in the
splicing of multiple targets. It is likely that titration of lev-
els of multiple splicing factors is required to "fine tune"
splicing decisions.
Conclusion
The relatively small number of aberrant pre-mRNA splic-
ing events that we observed in our GBM sample set sug-
gests that systematic, epigenetic targeting of splicing that
leads to large changes may not be an important mecha-
nism in gliomagenesis. Other exon array studies measur-
ing tumor-specific aberrant alternative pre-mRNA splicing
in prostate cancer and colon cancer also support the find-
ing that extreme splicing changes in cancer are less fre-
quent than was suggested by in silico studies
[29,33,40,46]. We found that only 612 of 20,157 (3%)
fully annotated RefSeq entries on the exon array showed
significant changes in exon expression. We interpret our
results to indicate that aberrant pre-mRNA splicing in
GBM is a low frequency event. However, this analysis does
not rule out patient- or gene-specific aberrant splicing
events, or smaller magnitude splicing changes with critical
functions in gliomagenesis. Furthermore, the differential
expression of several RNA processing factors not involved
in alternative splicing suggests that other aspects of RNA
biology may play critical roles in gliomagenesis. Our vali-
dation experiments indicate that GBM-specific splicing is
generally a partial event, with varying degrees of exon
inclusion. The 14 genes identified in our study are poten-
tially the most important GBM-specific splicing events
and constitute promising targets for therapeutic interven-
tion.
Methods
Cell line information
The U251, SNB19 and T98G cell lines were grown as pre-
viously described [30]. Morpholino oligonucleotides tar-
geting the intron splicing silencer sequences flanking
FGFR1 exon 3 was performed by double "scrape-loading"BMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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as previously described [30]. RNA isolation was per-
formed using the RNeasy Micro kit according to the
instructions provided (Qiagen, Valencia, CA).
Patient information
Informed consent was obtained from all patients prior to
sample collection in accordance with the guidelines set by
the Institutional Review Board. Biopsy samples from sur-
gical resections were collected and banked through the
brain tumor tissue bank at the Brain Tumor Center at the
University of Texas M. D. Anderson Cancer Center. All
samples were immediately placed on ice and snap-frozen
for -80°C storage within 30 min of devascularization after
removal of portions needed for pathological diagnosis.
We obtained 24 newly diagnosed primary glioblastoma
(WHO grade IV astrocytoma; K. Aldape) samples from
patients who received no therapy, but underwent gross
total resection before sample collection. Glioblastoma
samples contained at least 90% tumor. 12 frozen samples
of nonneoplastic brain tissue without histologic evidence
of tumor or another significant abnormality were used for
comparison. RT-PCR validation also included Human
Brain Total RNA, extracted from a 78-year-old Caucasian
female with congestive heart failure (Ambion, Austin,
TX).
RNA extraction
RNA was extracted using the TriZol Reagent according to
the manufacturer's suggestions (Invitrogen, Carlsbad, CA)
and further purified using the RNeasy kit. The quality and
integrity of the RNA was then analyzed on an Agilent Bio-
Analyzer (RNA 6000 Nano LabChip). Total cellular RNA
samples with a RIN (RNA integrity number) > 7 were used
for further microarray studies.
Microarray exon profiling
For exon profiling on the Human Exon Array 1.0 ST
(Affymetrix Santa Clara, CA), RNA was prepared using a
pre-commercial versions of the Affymetrix GeneChip
Whole Transcript (WT) Double-Stranded Target Labeling
Assay for preparation of double-stranded (ds) target DNA
(first generation protocol) or the Affymetrix GeneChip
Whole Transcript (WT) Sense Target Labeling Assay for
preparation of single-stranded (ss) target DNA (second
generation protocol). Precommercial versions of the kits,
containing identical formulations to the commercial kits,
were used for target preparation. For comparison a subset
of samples was prepared with both protocols; however,
samples prepared with the different protocols were not
mixed in subsequent analyses.
Double-stranded target preparation
100 ng of total RNA was added to a solution of 250 ng/μl
T7-(N)6 primer/poly(A) RNA control dilution for a total
volume of 5 μl. Samples were mixed and incubated at
70°C for 5 min and cooled at 4°C for 2 min. A first-cycle,
first strand cDNA synthesis mix was prepared by combin-
ing 2 μl of 5× first-strand buffer, 1 μl of 0.1 M DTT, 0.5 μl
of 10 mM dNTP mix, 0.5 μl of 40 U/μl RNase-Out and 1
μl of 200 U/μl SuperScript II. The first-cycle, first strand
cDNA synthesis mix was added to the total RNA T7-(N)6
primer/poly(A) RNA control for a total volume of 10 μl,
mixed, centrifuged and incubated at 25°C for 10 min,
42°C for 60 min, 70°C for 10 min and 4°C for 2 min. A
first-cycle, secondstrand cDNA synthesis was then pre-
pared using 4 μl of 17.5 mM MgCl2, 0.4 μl of 10 mM
dNTP Mix, 2.5μl of 5 U/μl Klenow 3' to 5' exo, 0.2 μl of 2
U/μl RNase H and 2.9 μl nuclease-free water. Ten μl from
the first-cycle, first strand cDNA synthesis reaction was
added for a total volume of 20 μl, mixed, centrifuged and
incubated at 37°C for 50 min, 75°C for 10 min, and 4°C
for 2 min. Using components from the MEGAscript T7 Kit
(Ambion, Austin, TX), 5 μl of 10× reaction buffer, 5 μl
ATP, 5 μl CTP, 5 μl UTP, 5 μl GTP and 5 μl enzyme mix
were combined with each reaction for a total volume of 50
μl. Reactions were incubated at 37°C for 16 hrs. Reactions
were then immediately cleaned using the cRNA Cleanup
Spin Columns from the GeneChip Sample Cleanup Mod-
ule (Affymetrix). One μl of the sample was used for cRNA
yield determination on the spectrophotometer; 15 μg of
cRNA was mixed with 9 μg of random primers and nucle-
ase free water for a reaction volume of 24 μl. Reactions
were incubated at 70°C for 5 min, 25°C for 5 min and
4°C for 2 min. A second-cycle, first-strand mix was pre-
pared using 12 μl 5× first-strand buffer, 6 μl of 0.1 M DTT,
3 μl of 10 mM dNTP mix with dUTP (Affymetrix), 3 μl of
40 U/μl RNase-Out and 12 μl of 200 U/μl SuperScript II;
36 μl of the second-cycle, firststrand mix was added to the
cRNA and random primers, mixed, centrifuged (60 μl
total) and each reaction was divided into 3 tubes of 20 μl.
Reactions were incubated at 25°C for 5 min, 42°C for 60
min, 70°C for 10 min, 4°C for 2 min. A second-cycle, sec-
ond-strand cDNA synthesis solution was prepared using
24 μl of 17.5 mM MgCl2, 1.8 μl of 10 mM dNTP mix with
dUTP (Affymetrix), 16.2 μl of 5 U/μl Klenow 3' to 5' exo,
1.5 μl of 2 U/μl RNase H and 16.5 μl nuclease-free water.
The three 20 μl reactions were combined into one tube
and 60 μl of secondcycle, second-strand cDNA synthesis
solution was added for a total of 120 μl. Reactions were
mixed, centrifuged and the samples were divided again
into 3 tubes of 40 μl each. Reactions were incubated at
37°C for 50 min, 75°C for 10 min and 4°C for 2 min.
Reactions were then cleaned using the cDNA Cleanup
Spin Columns from the GeneChip Sample Cleanup Mod-
ule (Affymetrix). Once cleaned the three tubes were com-
bined into one, mixed and measured on a
spectrophotometer. Twenty μg of double stranded (ds)
cDNA (up to 96.6 μl) was fragmented with 14.4 μl of 10×
NEB Buffer 4, 12 μl of 2 U/μl uracil DNA glycosylase and
21 μl of 10 U/μl APE 1. Reactions were mixed, centrifugedBMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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and then split into 3 tubes (48 μl each), incubated at 37°C
for 60 min, 93°C for 1 min and 4°C for 2 min. One μl was
removed from each tube for analysis on the Agilent Bio-
Analyzer using the RNA 6000 Nano LabChip. The three
tubes were combined again (up to 135 μl), and labeled
with 36 μl of 5× TdT Reaction Buffer, 6 μl of 30 U/μl rTDT
and 3 μl of GeneChip DNA Labeling Reagent DLR
(Affymetrix). Samples were mixed, centrifuged, divided
60 μl per tube and incubated at 37°C for 60 min and 4°C
for 2 min. The reactions were stopped by adding 2 μl of
0.5 M EDTA, combined into one tube and concentrated
using the YM-3 Microcon column.
Single-stranded target preparation
One μg of RNA was mixed with diluted (1:20, 1:50, 1:50)
Affymetrix poly(A) controls (2 μl) and a Ribo-Minus
probe (Invitrogen). The RNA was then ribo-reduced using
the Ribo-Minus Human/Mouse Transcriptome Isolation
Kit (Invitrogen). To dilute the Ribo-Minus probe, hybrid-
ization buffer was prepared by combining 45 μl of 5 M
betaine and 105 μl of Invitrogen hybridization buffer; 0.8
μl of the Ribo-Minus probe (100 pmol/μl) was diluted
with 30 μl hybridization buffer containing betaine and
then added to the RNA and poly(A) control mix. Reac-
tions were incubated at 70°C for 5 min. Magnetic beads
used for the ribo-reduction step were washed twice with
RNase-free water, once with hybridization buffer with
betaine and resuspended with 20 μl of hybridization
buffer with betaine. The magnetic beads were warmed at
37°C for 2 min prior to the addition of the RNA poly(A)
control probe. Following the 70°C incubation, the sam-
ples were immediately cooled on ice for 2 min. Samples
were then added to the magnetic beads, mixed, centri-
fuged and incubated at 37°C for 10 min with a mix after
5 min. Following incubation the samples were placed on
a magnetic stand for 5 min, and the supernatant was
removed and placed on ice. The beads were washed with
hybridization buffer and betaine and incubated at 50°C
for 5 min. The samples were then placed back on the mag-
netic stand for 5 min, and the supernatant was removed
and placed on ice. The rRNA-reduced RNA was concen-
trated using the GeneChip IVT cRNA Cleanup Kit
(Affymetrix). One μl of concentrated RNA was analyzed
on an Agilent BioAnalyzer using the RNA 6000 Nano
LabChip to check the quality and percent of ribosomal
reduction of the starting material. Percent ribosomal
reduction of the RNA ranged between 60–90%. Four μl of
ribosomal reduced RNA was added to 500 ng/μl of T7-
(n)6 primers for a total of 5 μl and incubated for 5 min at
70°C, 5 min at 25°C and cooled for 2 min at 4°C. Using
components from the GeneChip WT Double Stranded
cDNA Synthesis Module (Affymetrix) 2 μl of 5× 1st strand
buffer, 1 μl of DTT 0.1 M, 0.5 μl of dNTP 10 mM, 0.5 μl of
RNase Inhibitor and 1 μl SuperScript II 200 U/μl) were
combined and added to the concentrated rRNA-Reduced
total RNA/poly(A) RNA controls/T7-(N)6 primers for a
total of 10 μl. Reactions were incubated at 25°C for 10
min, 42°C for 60 min, 70°C for 10 min, 4°C for 2 min. A
first-cycle, second-strand solution was then prepared
again using the GeneChip WT Double Stranded cDNA
Synthesis Module and added to each sample (4 μl of 17.5
mM MgCl2, 0.4 μl of 10 mM dNTP mix, 0.6 μl of DNA
polymerase I, 0.2 μl of RNase H, and RNase-free water for
a total reaction volume of 20 μl). Reactions were mixed
and incubated at 16°C for 2 hrs, 75°C for 10 min and 4°C
for 2 min. An IVT solution was prepared using the Gene-
Chip WT cDNA Amplification Kit (Affymetrix; 5 μl of 10×
IVT buffer, 20 μl of IVT NTP mix and 5 μl of IVT Enzyme
mix), added to each reaction and allowed to incubate at
37°C for 16 hrs. Reactions were immediately cleaned up
using the cRNA Cleanup Spin Columns from the Gene-
Chip Sample Cleanup Module (Affymetrix). The second
cycle, first-strand cDNA synthesis was prepared by adding
8 μg of cRNA with 4.5 μg of random primer and RNAse-
free water for a total volume of 8 μl and incubated at 70°C
for 5 min, 25°C for 5 min, and cooled at 4°C for 2 min.
The second-cycle reverse transcription mix was prepared
using the GeneChip WT cDNA Amplification Kit (Affym-
terix) by combining 4 μl 5× 1st Strand Buffer, 2 μl DTT 0.1
M, 1.25 μl 10 mM dNTP+dUTP 10 mM, and 4.75 μl of
SuperScript II 200 U/μl. This was immediately added to
the second-cycle, first-strand cDNA synthesis upon cool-
ing. Reactions were then mixed and incubated at 25°C for
10 min, 42°C for 90 min, 70°C for 10 min, 4°C for 2
min. One μl of RNase H was then added to each sample
for hydrolysis of the dsDNA and incubated at 37°C for 45
min, 95°C for 5 min and 4°C for 2 min. Reactions were
then cleaned using the cDNA Cleanup Spin Columns
from the GeneChip Sample Cleanup Module. Five μg of
single-stranded (ss) DNA was then fragmented and
labeled using the Gene Chip WT Double Stranded DNA
Terminal Labeling Kit (Affymetrix; 4.8 μl of 10× cDNA
Fragmentation Buffer, 1 μl of 10 U/μl of UDG, and 1 μl of
1000 U/μl of APE 1). Samples were mixed and incubated
at 37°C for 60 min, 93°C for 2 min and 4°C for 2 min.
Two μl of this reaction was saved for analysis on the Agi-
lent BioAnalyzer using the RNA 6000 Nano LabChip. The
remainder of the sample was labeled with 12 μl of 5× TdT
Buffer, 2 μl of TdT and 1 μl of 5 mM DNA labeling reagent
for a total volume of 60 μl. Reactions were mixed and
incubated at 37°C for 60 min, 70°C for 10 min and 4°C
for 2 min. Five μg of either dsDNA or ssDNA target prep-
arations were hybridized with 50 pM oligonucleotide B2,
20× Eukaryotic Hybridization Controls (bioB, bioC,
bioD, cre) at 1.5, 5, 5 and 100 pm, 0.1 mg/ml herring
sperm DNA, 0.5 mg/ml acetylated BSA, 1× hybridization
buffer, 7% DMSO and up to 220 μl RNase-free water.
Reactions were mixed and briefly centrifuged then incu-
bated at 99°C for 5 min, cooled to 45°C for 5 min and
then centrifuged at maximum speed for 1 min to collectBMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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precipitate. Exon arrays were equilibrated to room tem-
perature prior to injection; 200 μl of the hybridization
solution was added to each array and incubated in a rotat-
ing hybridization oven (Affymetrix) at 45°C and 60 rpm
for 16 hrs. Following hybridization, the arrays were
washed and stained on an Affymetrix Fluidics 450 work-
station using the FS450_0001 fluidics script, and scanned
on an Affymetrix GeneChip 3000. GeneChip Operating
Software (GCAS) v1.3 was used to produce .cel intensity
files.
Exon array data analysis
Exon arrays were quantified using the PLIER algorithm
introduced by Affymetrix. The arrays were quantile-nor-
malized, and GC-specific background was estimated and
subtracted using the PM-GCBG option. All quantifica-
tions used log2(PLIER + 8) values, where the value "8" is
an arbitrary shrinkage constant. PLIER summarizes
groups of probe-level intensities, and we used two differ-
ent groupings: (1) all probes within a single PSR, and (2)
all probes within a given gene. Genes were defined as Ref-
Seq clusters using groupings of PSRs supplied by Affyme-
trix. While many PSRs on the array are not part of a RefSeq
cluster, we chose to focus primarily on those where we
had good annotation. Exon numbering within the gene
was checked by mapping the reported sequences against
data from the UCSC genome browser (Build 16).
Alternative splicing
In order to identify alternative splicing within a gene, we
determined instances where the PSR-level quantifications
differed significantly from the gene-level quantifications.
For example, let us consider the case of a hypothetical
gene with several component PSRs (Gene A). The gene-
level PLIER quantifications suggest mean log2 intensities
of 8 in GBMs and 7 in nontumor brain (a two-fold
increase in expression in GBMs). Quantifications of the
first PSR suggest mean values of 7 in GBMs and 6 in non-
tumor brain, again showing a two-fold increase in the
GBMs, consistent with the overall behavior of the gene.
Taking the mean difference for the PSR (7 - 6 = 1), we sub-
tract the mean difference for the gene (8 - 7 = 1) to get the
amount by which the behavior of the PSR differs from that
of the overall gene; large differences specific to the PSR
indicate potential alternative splicing. While "large" can
be assessed in terms of fold-change, we prefer to scale the
observed (PSR change) – (gene change) by an estimate of
the within group (GBM or nontumor) standard deviation,
as in a standard t-test. For example, let us assume that
these differences for one PSR have values of (0 - 2, 0 - 1, 0,
0 + 1, 0 + 2) for the GBM and (2 - 2, 2 - 1, 2, 2 + 1, 2 + 2)
for the nontumor samples. The mean difference between
groups is 2. Now let us assume that for another PSR we see
(0 - 6, 0 - 3, 0, 0 + 3, 0 + 6) vs. (2 - 6, 2 - 3, 2, 2 + 3, 2 + 6).
The mean difference (on a log2 scale) is still 2, but the var-
iability is a lot higher. The latter PSR would get a smaller
t-value than the former, since the signal does not stand
out as clearly above the noise. This approach is very simi-
lar to starting with a standard two-way Analysis of Vari-
ance (ANOVA) with main effects for condition (GBM or
nontumor) and PSR, and testing for a significant interac-
tion between condition and PSR. There, the scaled PSR –
gene differences are squared and summed to give the test
statistic. However, since we are looking for differences in
cassette exons (a very small number of PSRs), and sum-
ming spreads the differences across several PSRs, we
decided to work first with the squared terms for each indi-
vidual PSR and look at the size of the largest of these terms
[the maxT2, which is our Alternative Splicing (AS) score].
This, in turn, is similar to the ANalysis of Splice Variation
(ANOSVA [47]) save that separate variance estimates are
computed for each PSR. This focus on PSR-specific varia-
tion also differs from the correlation-based method used
by French et al. [40]. We estimated the null distribution of
this statistic through simulations. Some of the PSRs found
using this approach were driven by a combination of
"dead probes" and gene-level differential expression: e.g.,
the mean level of gene expression went from 6 in the
GBMs to 9 in the nontumor, but the values for one PSR
stayed fixed at 3 throughout. While this PSR behaves dif-
ferently from the rest of the gene, it may be doing so
because the probes simply fail to hybridize to the target at
all. In order to address this problem, we added a further
filtration step. First, every PSR was assessed a prior proba-
bility of being measurable by taking the PLIER values
across all samples from PSRs that were part of a RefSeq
gene, forming a histogram, and modeling these expres-
sion values as coming from a mixture of a normal distri-
bution (noise) and an exponential distribution (signal).
Then, using the estimated parameters of the normal distri-
bution, the prior probability with mean intensity × is
normcdf(x, mu+3 * sigma, sigma2). PSRs close to the
noise level are not likely to be measurable. Based on the
observed data, this prior is updated to give a posterior dis-
tribution suggesting whether the PSR is measurable. If the
PSR shows reasonable variation or difference in expres-
sion between conditions, the posterior probability of
measurability should be near certainty. Updating was per-
formed by computing p-values for PSR specific t-tests
without adjusting for gene-level differences; the associ-
ated p-values were then used to compute posterior odds
using the method of Sellke et al. [48]. We then computed
p-values (using the conservative assumption that the
maxT2 distribution was the maximal order statistic from k
independent tests) for each inclusion/exclusion combina-
tion, i.e., there are 2k-k-1 possible combinations of "include
this PSR, exclude that one" for defining a gene if we omit
the null cases of 0 or 1 PSRs from consideration. For each
such combination, we compute a T2 value and p-value as
noted above, and we also assign a weight proportional toBMC Genomics 2008, 9:216 http://www.biomedcentral.com/1471-2164/9/216
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the product of the probabilities of inclusion (exclusion)
used. The weighted sum of these is the p-value reported
here. In the case of the "dead" PSR discussed above, the
terms with that PSR included would have small p-values
(it is different from all of the others), but low weight
(because that PSR is deemed not measurable), and the
final weighted p-value will be large.
We also determined modal values of the test statistic via
simulation. Our simulations assumed the "ideal case."
The mean expression levels for individual PSRs were cho-
sen from the interval [3,12], reflecting the range of log2
PLIER scores observed; normal noise was added. Variabil-
ity was allowed to be different for each PSR, with the var-
iance drawn at random from the set of PSR variances
observed in our studies. Pooled variance estimates were
used. Differences were concentrated in a single PSR, with
the size of the difference being log2 of 5, 10, or 20, respec-
tively. A difference of 0 was also examined to supply esti-
mates of the null distribution. Simulations were run for
genes involving 4, 8 and 20 exons.
Differential expression
Differential expression at the gene level was assessed using
2-sample t-tests. This is our measure of Differential Expres-
sion (DE). We corrected for multiple testing by using beta-
uniform mixture (BUM) models [49] and targeting a false-
discovery rate (FDR) of 5%. An arbitrary constant (0.1)
was added to the pooled variance estimates before the t-
statistics were computed to ensure a certain minimal fold-
change that was statistically significant.
Microarray expression profiling
Target preparation
For RNA expression profiling on the U133 Plus 2 Gene-
Chip (Affymetrix, Santa Clara, CA), a total of 5 μg of total
cellular RNA from each sample was used for cDNA synthe-
sis according to the manufacturer's protocol. Briefly, a
mixture of in vitro transcribed cRNAs of cloned bacterial
genes for lysA, pheB, thrB, and dap (American Type Culture
Collection) was added as external controls to monitor the
efficiency of cRNA synthesis. First-strand cDNA synthesis
was performed at 42°C for 1 hr with the Superscript II sys-
tem (GIBCO/BRL) at a final concentration of 1× first-
strand synthesis buffer, 10 mM DTT, 500 μM dNTPs, 100
pmol of T7-(T)24 primer, and 200 units of reverse tran-
scriptase. Second-strand cDNA synthesis was performed at
16°C for 2 hr at a final concentration of 1× second-strand
buffer, 250 μM dNTP, 65 U/ml DNA ligase, 250 units/ml
DNA polymerase I, 13 U/ml RNase H. Second-strand syn-
thesis reaction mixtures were cleaned up with an Affyme-
trix cDNA purication column. In vitro transcription
labelling with biotinylated UTP and CTP was performed
according to the manufacturer's recommendations (Enzo
Diagnostics) for 16 hr at 37°C. Amplified cRNA was puri-
fied on a cRNA purification column (RNeasy, Qiagen),
and the quality of the amplification was verified by anal-
ysis on an Agilent BioAnalyzer. Labelled cRNAs were frag-
mented for 35 min at 94°C in 40 mM Tris-acetate, pH 8.1/
100 mM KOAc/30 mM Mg(OAc)2. The hybridization
cocktail consisted of 10 μg fragmented cRNA in 200 μl,
containing 50 pM control oligonucleotide B2, 0.1 mg/ml
herring sperm DNA, 0.5 mg/ml acetylated BSA, 100 mM
Mes, 20 mM EDTA, 0.01% Tween 20 (total Na+ = 1 M),
and bacterial sense cRNA controls for bioB, bioC, bioD, and
cre at 1.5, 5.0, 25, and 100 pM, respectively. Fragmented
cRNAs were then hybridized to Affymetrix U133Plus2
GeneChips and scanned according to the manufaturer's
protocol.
Expression array data analysis
For the U133 Plus 2.0 expression array, we identified a
comprehensive set of 499 probe sets representing RNA
processing factors (RPFs) with known functions in general
and alternative splicing, RNA export, RNA degradation,
miRNA processing and nonsense-mediated decay (see
Additional file 9). Gene-level RMA quantifications were
used for unsupervised clustering analysis on the 499
probe sets. To identify the most relevant RPFs, we per-
formed two-sample t-tests for each gene to contrast the
groups revealed by the clustering analysis. Values with a p-
value < 0.05 were extracted and sorted by the difference in
mean expression between the two groups. Values for the
top 25 positive or negative mean expression differences
were then used to perform a second clustering analysis
shown in Figure 4.
RT-PCR validations
cDNA was generated from 2 μg of DNaseI treated brain,
tumor, or cell line RNA using standard methods. Equal
amounts of random decamer and oligo-(dT) primed
cDNA were pooled and diluted to 200 μl with molecular
grade H2O. For PCR, 5 μl for patient samples and 3 μl for
glioma cell lines of cDNA were used. PCR was carried out
in 1× PCR buffer (Invitrogen, Carlsbad, USA), 1.5 mM
MgCl2, 0.25 mM dNTPs, 20 pmol of each forward and
reverse primer (for primers see Additional file 111), and
2.5 U of Taq Polymerase (Invitrogen, Carlsbad, USA). The
reaction was carried out for 35–37 cycles at 55–62°C
annealing depending on the primer set and transcript
abundance. The PCR products were electrophoresed on
1% agarose gels and visualized with ethidium bromide
staining.
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